Hood_老虎社区_美港股上老虎

CocoaGinger
2021-10-14

Hood

J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study<blockquote>在NIH研究中，强生COVID-19疫苗从Moderna或辉瑞获得更好的促进作用</blockquote>

Oct 13 (Reuters) - People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a str

J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study<blockquote>在NIH研究中，强生COVID-19疫苗从Moderna或辉瑞获得更好的促进作用</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":822788968,"tweetId":"822788968","gmtCreate":1634171595495,"gmtModify":1634171595495,"author":{"id":4091873312406950,"idStr":"4091873312406950","authorId":4091873312406950,"authorIdStr":"4091873312406950","name":"CocoaGinger","avatar":"https://static.tigerbbs.com/d22eef7f8a3a992c9290b3825767a279","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Hood</body></html>","htmlText":"<html><head></head><body>Hood</body></html>","text":"Hood","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/822788968","repostId":1184925340,"repostType":4,"repost":{"id":"1184925340","kind":"news","pubTimestamp":1634171292,"share":"https://www.laohu8.com/m/news/1184925340?lang=zh_CN&edition=full","pubTime":"2021-10-14 08:28","market":"us","language":"en","title":"J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study<blockquote>在NIH研究中，强生COVID-19疫苗从Moderna或辉瑞获得更好的促进作用</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184925340","media":"Reuters","summary":"Oct 13 (Reuters) - People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a str","content":"Oct 13 (Reuters) - People who got Johnson &amp; Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc /BioNTech SE or Moderna Inc, a study run by the National Institutes of Health showed on Wednesday.<blockquote>路透10月13日-美国国立卫生研究院（National Institutes of Health）周三进行的一项研究显示，第一针接种强生公司（Johnson&amp;Johnson Inc.）新冠肺炎疫苗的人在接种辉瑞公司（Pfizer Inc/BioNTech SE）或Moderna Inc.的疫苗后，免疫反应更强。</blockquote> The study, which is preliminary and hasn't been peer reviewed, is the latest challenge to J&amp;J's efforts to use its COVID-19 vaccine as a booster in the United States.<blockquote>这项研究是初步的，尚未经过同行评审，是对强生在美国使用其COVID-19疫苗作为加强剂的努力的最新挑战。</blockquote> The study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson &amp; Johnson, showed that \"mixing and matching\" booster shots of different types is safe in adults. Moderna's and Pfizer's vaccines are based on messenger RNA while J&amp;J's uses viral vector technology.<blockquote>这项研究包括450多名接受辉瑞、Moderna或强生公司初始注射的成年人，研究表明，“混合和匹配”不同类型的加强注射对成年人是安全的。Moderna和辉瑞的疫苗基于信使RNA，而强生的疫苗使用病毒载体技术。</blockquote> It comes as an advisory group to the U.S. Food and Drug Administration is preparing to meet later this week to discuss the merits of a booster shot for Moderna and J&amp;J vaccines.<blockquote>它是美国的一个咨询小组。美国食品药品监督管理局正准备在本周晚些时候召开会议，讨论Moderna和J&amp;J疫苗加强注射的优点。</blockquote> FDA officials on Wednesday said J&amp;J's regulatory submission for its planned booster raised red flags including small sample sizes and data based on tests that had not been validated.<blockquote>FDA官员周三表示，强生公司向监管机构提交的计划加强剂引发了危险信号，包括样本量小和基于未经验证的测试的数据。</blockquote> U.S. health officials have been under pressure to offer advice on booster doses of the J&amp;J and Moderna COVID-19 vaccines after the White House announced in August it planned to roll out boosters beginning last month for most adults.<blockquote>在白宫8月份宣布计划从上个月开始为大多数成年人推出加强疫苗后，美国卫生官员一直面临着就强生和Moderna COVID-19疫苗加强剂量提供建议的压力。</blockquote> The NIH study contrasted the safety and immune response of volunteers who were boosted with the same type of shot they had been given for their initial vaccination with those who received a different type of shot as a booster.<blockquote>美国国立卫生研究院的研究对比了接受与初次疫苗接种相同类型疫苗加强注射的志愿者与接受不同类型疫苗加强注射的志愿者的安全性和免疫反应。</blockquote> Mixing and matching doses for a booster produced similar side effects to those seen in primary inoculations and raised no significant safety concerns, the study said.<blockquote>研究称，混合和匹配加强剂的剂量会产生与初次接种相似的副作用，并且不会引起重大的安全问题。</blockquote> The study of the three COVID-19 vaccines currently authorized in the United States showed that using different types of shots as boosters generally appeared to produce a comparable or higher antibody response than using the same type.<blockquote>对美国目前授权的三种新冠肺炎疫苗的研究表明，使用不同类型的疫苗作为加强剂通常会产生与使用相同类型相当或更高的抗体反应。</blockquote> The trial took place in 10 U.S. cities and used a total of nine combinations of initial shots and boosters.<blockquote>该试验在美国10个城市进行，总共使用了9种初始注射和加强注射的组合。</blockquote> Mixing booster doses \"may offer immunological advantages to optimize the breadth and longevity of protection achieved with currently available vaccines,\" researchers wrote in the study.<blockquote>研究人员在研究中写道，混合加强剂量“可能会提供免疫学优势，以优化目前可用疫苗实现的保护范围和寿命”。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study<blockquote>在NIH研究中，强生COVID-19疫苗从Moderna或辉瑞获得更好的促进作用</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study<blockquote>在NIH研究中，强生COVID-19疫苗从Moderna或辉瑞获得更好的促进作用</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-10-14 08:28\n\n</h4>\n</header>\n<article>\nOct 13 (Reuters) - People who got Johnson &amp; Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc /BioNTech SE or Moderna Inc, a study run by the National Institutes of Health showed on Wednesday.<blockquote>路透10月13日-美国国立卫生研究院（National Institutes of Health）周三进行的一项研究显示，第一针接种强生公司（Johnson&amp;Johnson Inc.）新冠肺炎疫苗的人在接种辉瑞公司（Pfizer Inc/BioNTech SE）或Moderna Inc.的疫苗后，免疫反应更强。</blockquote> The study, which is preliminary and hasn't been peer reviewed, is the latest challenge to J&amp;J's efforts to use its COVID-19 vaccine as a booster in the United States.<blockquote>这项研究是初步的，尚未经过同行评审，是对强生在美国使用其COVID-19疫苗作为加强剂的努力的最新挑战。</blockquote> The study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson &amp; Johnson, showed that \"mixing and matching\" booster shots of different types is safe in adults. Moderna's and Pfizer's vaccines are based on messenger RNA while J&amp;J's uses viral vector technology.<blockquote>这项研究包括450多名接受辉瑞、Moderna或强生公司初始注射的成年人，研究表明，“混合和匹配”不同类型的加强注射对成年人是安全的。Moderna和辉瑞的疫苗基于信使RNA，而强生的疫苗使用病毒载体技术。</blockquote> It comes as an advisory group to the U.S. Food and Drug Administration is preparing to meet later this week to discuss the merits of a booster shot for Moderna and J&amp;J vaccines.<blockquote>它是美国的一个咨询小组。美国食品药品监督管理局正准备在本周晚些时候召开会议，讨论Moderna和J&amp;J疫苗加强注射的优点。</blockquote> FDA officials on Wednesday said J&amp;J's regulatory submission for its planned booster raised red flags including small sample sizes and data based on tests that had not been validated.<blockquote>FDA官员周三表示，强生公司向监管机构提交的计划加强剂引发了危险信号，包括样本量小和基于未经验证的测试的数据。</blockquote> U.S. health officials have been under pressure to offer advice on booster doses of the J&amp;J and Moderna COVID-19 vaccines after the White House announced in August it planned to roll out boosters beginning last month for most adults.<blockquote>在白宫8月份宣布计划从上个月开始为大多数成年人推出加强疫苗后，美国卫生官员一直面临着就强生和Moderna COVID-19疫苗加强剂量提供建议的压力。</blockquote> The NIH study contrasted the safety and immune response of volunteers who were boosted with the same type of shot they had been given for their initial vaccination with those who received a different type of shot as a booster.<blockquote>美国国立卫生研究院的研究对比了接受与初次疫苗接种相同类型疫苗加强注射的志愿者与接受不同类型疫苗加强注射的志愿者的安全性和免疫反应。</blockquote> Mixing and matching doses for a booster produced similar side effects to those seen in primary inoculations and raised no significant safety concerns, the study said.<blockquote>研究称，混合和匹配加强剂的剂量会产生与初次接种相似的副作用，并且不会引起重大的安全问题。</blockquote> The study of the three COVID-19 vaccines currently authorized in the United States showed that using different types of shots as boosters generally appeared to produce a comparable or higher antibody response than using the same type.<blockquote>对美国目前授权的三种新冠肺炎疫苗的研究表明，使用不同类型的疫苗作为加强剂通常会产生与使用相同类型相当或更高的抗体反应。</blockquote> The trial took place in 10 U.S. cities and used a total of nine combinations of initial shots and boosters.<blockquote>该试验在美国10个城市进行，总共使用了9种初始注射和加强注射的组合。</blockquote> Mixing booster doses \"may offer immunological advantages to optimize the breadth and longevity of protection achieved with currently available vaccines,\" researchers wrote in the study.<blockquote>研究人员在研究中写道，混合加强剂量“可能会提供免疫学优势，以优化目前可用疫苗实现的保护范围和寿命”。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/1-j-j-shot-performs-205735569.html\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","JNJ":"强生","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/1-j-j-shot-performs-205735569.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184925340","content_text":"Oct 13 (Reuters) - People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc /BioNTech SE or Moderna Inc, a study run by the National Institutes of Health showed on Wednesday.\nThe study, which is preliminary and hasn't been peer reviewed, is the latest challenge to J&J's efforts to use its COVID-19 vaccine as a booster in the United States.\nThe study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson & Johnson, showed that \"mixing and matching\" booster shots of different types is safe in adults. Moderna's and Pfizer's vaccines are based on messenger RNA while J&J's uses viral vector technology.\nIt comes as an advisory group to the U.S. Food and Drug Administration is preparing to meet later this week to discuss the merits of a booster shot for Moderna and J&J vaccines.\nFDA officials on Wednesday said J&J's regulatory submission for its planned booster raised red flags including small sample sizes and data based on tests that had not been validated.\nU.S. health officials have been under pressure to offer advice on booster doses of the J&J and Moderna COVID-19 vaccines after the White House announced in August it planned to roll out boosters beginning last month for most adults.\nThe NIH study contrasted the safety and immune response of volunteers who were boosted with the same type of shot they had been given for their initial vaccination with those who received a different type of shot as a booster.\nMixing and matching doses for a booster produced similar side effects to those seen in primary inoculations and raised no significant safety concerns, the study said.\nThe study of the three COVID-19 vaccines currently authorized in the United States showed that using different types of shots as boosters generally appeared to produce a comparable or higher antibody response than using the same type.\nThe trial took place in 10 U.S. cities and used a total of nine combinations of initial shots and boosters.\nMixing booster doses \"may offer immunological advantages to optimize the breadth and longevity of protection achieved with currently available vaccines,\" researchers wrote in the study.","news_type":1,"symbols_score_info":{"JNJ":0.9,"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3786,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study<blockquote>在NIH研究中，强生COVID-19疫苗从Moderna或辉瑞获得更好的促进作用</blockquote>

评论（1）

热议股票